Core Viewpoint - The project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," completed with the participation of Yuanzi Gaoke Co., Ltd., has won the first prize of the Beijing Medical Science and Technology Award this year [1] Group 1: Project Significance - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a 5-year survival rate of less than 50% [1] - The project addresses a significant public health issue affecting children's health in China, focusing on the challenges posed by neuroblastoma, referred to as the "king of childhood cancers" [1] Group 2: Technological Innovation - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, after ten years of systematic research [1] - It has developed a multimodal, low-dose, and short-duration nuclear medicine molecular imaging precision diagnosis and treatment system for neuroblastoma, contributing Chinese wisdom and solutions to this global challenge [1]

（股份代號：1763） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於其他海外監管市場發佈的公告 公司附屬公司榮獲北京醫學科技獎一等獎 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年12月15日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司關於參與「兒童神經母細胞 瘤多模態核醫學分子影像體系的建立」項目榮獲北京醫學科技獎一等獎的公告」， 僅供參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年12月15日 於 ...

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [30]. Core Insights - Novartis' radioligand therapy drug Pluvicto has received approval for two indications in China, which is expected to boost the domestic nuclear medicine industry [3]. - BeiGene has raised its revenue guidance for 2025, now expecting between RMB 362 billion and RMB 381 billion, driven by strong product sales and improved operational efficiency [3]. Summary by Sections Industry Overview - Novartis' Pluvicto is approved for treating specific types of prostate cancer, with projected sales of USD 1.389 billion (approximately RMB 9.9 billion) for the first three quarters of 2025 [3]. - The approval of Pluvicto is anticipated to stimulate growth in the nuclear medicine sector, with a focus on companies leading in new isotopes and targets, such as Dongcheng Pharmaceutical and Yunnan Baiyao [3]. Company Performance - BeiGene's revenue for the first three quarters of 2025 reached RMB 275.95 billion, a year-on-year increase of 44.2%, surpassing the total revenue of RMB 272.1 billion for the previous year [3]. - The company has adjusted its 2025 revenue guidance upwards due to strong growth from its leading product, Brukinsa (Zebutinib), in the U.S. market and ongoing expansion in Europe and other key markets [3]. Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as Heng Rui Medicine and BeiGene, as well as those with high potential single products like Yipin Hong and Sanofi [5]. - It also highlights the importance of companies with leading positions in cutting-edge technology platforms, such as Dongcheng Pharmaceutical and Yuanda Medicine [5].

Core Viewpoint - China Tongdun (01763) reported its mid-year performance for 2025, showing a mixed financial outcome with revenue growth but a decline in profit before tax [1] Financial Performance - The company achieved operating revenue of 831 million, representing a year-on-year increase of 4.24% [1] - The total profit amounted to 171 million, reflecting a year-on-year decrease of 1.93% [1] - The net profit reached 148 million, indicating a year-on-year growth of 4.55% [1]

Group 1 - The core viewpoint of the article highlights the significant breakthroughs achieved by the research team at Nanhua University in the extraction and purification of medical isotopes, particularly strontium-90 and yttrium-90, from high-level waste liquid [1][3] - The team has developed a complete technical system for the separation, purification, and drug preparation of yttrium-90, addressing China's reliance on imports for this isotope [3][4] - The innovative techniques include the use of crown ether supramolecular design and new adsorption materials, which enable efficient capture of strontium-90 from nuclear waste [3][4] Group 2 - The future market demand for yttrium-90 in China is expected to be substantial, but current domestic technologies for its preparation and clinical application require further development [3] - The research team aims to tackle the large-scale production technology of lead-212 and establish a thorium-based isotope factory, positioning itself to become the largest producer of medical alpha isotopes globally [4] - The team is also focused on the research and clinical translation of new nuclear drugs, including lead-212 and bismuth-212 labeled drugs [4]